Stocks News

LAST PRICE
140.7100
TODAY'S CHANGE (%)
Trending Up0.8800 (0.6293%)

Bid / Lots
130.0000/ 1
Ask / Lots
150.0000/ 7
Open / Previous Close
140.9000 / 139.8300
Day Range
Low 139.2300
High 141.8800
52 Week Range
Low 89.0400
High 148.3699
Volume
616,567
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Today
- DJ Neurocrine Is Maintained at Neutral by Citigroup, from 3 hours ago by Dow Jones
  3 hours ago by Dow Jones
  Companies Mentioned: NBIX
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/NBIX/analyst-ratings
  
  (END) Dow Jones Newswires
  
  May 03, 2024 18:12 ET (22:12 GMT)
- Neurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024, from 8 hours ago by PR Newswire
  8 hours ago by PR Newswire
  Companies Mentioned: NBIX
  -- CAHtalyst™ Pediatric Study Baseline Characteristics Data Highlight Need for Novel Treatments in Children and Adolescents with Congenital Adrenal Hyperplasia (CAH)
  -- CAHtalog™ Registry Data of Glucocorticoid Treatment Patterns in Pediatric and Adult Patients Illustrates the Challenges of Long-Term CAH Management
- Neurocrine Biosciences Presented CAHtalyst(TM) Pediatric Study Baseline Characteristics and CAHtalog(TM) Registry Data at PES 2024, from 8 hours ago by Dow Jones
  8 hours ago by Dow Jones
  Companies Mentioned: NBIX
  
  Facebook.
  
  (*in collaboration with AbbVie)
  
  The NEUROCRINE BIOSCIENCES Logo Lockup and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc. The Neurocrine logo, CAHtalyst and CAHtalog are trademarks of Neurocrine Biosciences, Inc.
Yesterday
- DJ Neurocrine Is Maintained at Buy by Canaccord Genuity, from 3:29PM ET on Thursday May 02, 2024 by Dow Jones
  3:29PM ET on Thursday May 02, 2024 by Dow Jones
  Companies Mentioned: NBIX
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/NBIX/analyst-ratings
  
  (END) Dow Jones Newswires
  
  May 02, 2024 15:29 ET (19:29 GMT)
- DJ Neurocrine Is Maintained at Buy by Guggenheim, from 2:33PM ET on Thursday May 02, 2024 by Dow Jones
  2:33PM ET on Thursday May 02, 2024 by Dow Jones
  Companies Mentioned: NBIX
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/NBIX/analyst-ratings
  
  (END) Dow Jones Newswires
  
  May 02, 2024 14:33 ET (18:33 GMT)

Today
- Medpace Holdings Insider Sold Shares Worth $6,553,671, According to a Recent SEC Filing, from 5 hours ago by MT Newswires
  5 hours ago by MT Newswires
  Companies Mentioned: MEDP
Yesterday
- Alnylam Pharmaceuticals' Q1 Non-GAAP Net Loss Narrows as Revenue Increases; 2024 Outlook Affirmed, from 9:04AM ET on Thursday May 02, 2024 by MT Newswires
  9:04AM ET on Thursday May 02, 2024 by MT Newswires
  Companies Mentioned: ALNY
- -- Earnings Flash (ALNY) ALNYLAM PHARMACEUTICALS Posts Q1 Revenue $494.3M, vs. Street Est of $426.9M, from 8:02AM ET on Thursday May 02, 2024 by MT Newswires
  8:02AM ET on Thursday May 02, 2024 by MT Newswires
  Companies Mentioned: ALNY
- Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity, from 8:00AM ET on Thursday May 02, 2024 by Business Wire
  8:00AM ET on Thursday May 02, 2024 by Business Wire
  Companies Mentioned: ALNY
May 1, 2024
- Medpace Holdings Insider Sold Shares Worth $6,782,987, According to a Recent SEC Filing, from 4:59PM ET on Wednesday May 01, 2024 by MT Newswires
  4:59PM ET on Wednesday May 01, 2024 by MT Newswires
  Companies Mentioned: MEDP
Apr 30, 2024
- Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia, from 7:01AM ET on Tuesday Apr 30, 2024 by PR Newswire
  7:01AM ET on Tuesday Apr 30, 2024 by PR Newswire
  Companies Mentioned: ALNY
- Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia, from 7:00AM ET on Tuesday Apr 30, 2024 by CNW Group
  7:00AM ET on Tuesday Apr 30, 2024 by CNW Group
  Companies Mentioned: ALNY
Apr 29, 2024
- Qiagen Q1 Adjusted Earnings, Sales Decline; Q2 Outlook Issued, 2024 Guidance Affirms -- Shares Fall After Hours, from 4:48PM ET on Monday Apr 29, 2024 by MT Newswires
  4:48PM ET on Monday Apr 29, 2024 by MT Newswires
  Companies Mentioned: QGEN
- BioMarin Pharmaceutical Investors Overfocused on Roctavian, Distracted From Enzyme Replacement Therapies, UBS Says, from 2:26PM ET on Monday Apr 29, 2024 by MT Newswires
  2:26PM ET on Monday Apr 29, 2024 by MT Newswires
  Companies Mentioned: BMRN
Apr 25, 2024
- Scotiabank Adjusts Price Target on BioMarin Pharmaceutical to $83 From $85, Maintains Sector Perform Rating, from 11:43AM ET on Thursday Apr 25, 2024 by MT Newswires
  11:43AM ET on Thursday Apr 25, 2024 by MT Newswires
  Companies Mentioned: BMRN

Neurocrine Biosciences Inc
NASDAQ:NBIXUnited States

Search Criteria

Today

DJ Neurocrine Is Maintained at Neutral by Citigroup, from 3 hours ago by Dow Jones

Neurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024, from 8 hours ago by PR Newswire

Neurocrine Biosciences Presented CAHtalyst(TM) Pediatric Study Baseline Characteristics and CAHtalog(TM) Registry Data at PES 2024, from 8 hours ago by Dow Jones

Yesterday

DJ Neurocrine Is Maintained at Buy by Canaccord Genuity, from 3:29PM ET on Thursday May 02, 2024 by Dow Jones

DJ Neurocrine Is Maintained at Buy by Guggenheim, from 2:33PM ET on Thursday May 02, 2024 by Dow Jones

Peers Headlines

Today

Medpace Holdings Insider Sold Shares Worth $6,553,671, According to a Recent SEC Filing, from 5 hours ago by MT Newswires

Yesterday

Alnylam Pharmaceuticals' Q1 Non-GAAP Net Loss Narrows as Revenue Increases; 2024 Outlook Affirmed, from 9:04AM ET on Thursday May 02, 2024 by MT Newswires

-- Earnings Flash (ALNY) ALNYLAM PHARMACEUTICALS Posts Q1 Revenue $494.3M, vs. Street Est of $426.9M, from 8:02AM ET on Thursday May 02, 2024 by MT Newswires

Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity, from 8:00AM ET on Thursday May 02, 2024 by Business Wire

May 1, 2024

Medpace Holdings Insider Sold Shares Worth $6,782,987, According to a Recent SEC Filing, from 4:59PM ET on Wednesday May 01, 2024 by MT Newswires

Apr 30, 2024

Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia, from 7:01AM ET on Tuesday Apr 30, 2024 by PR Newswire

Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia, from 7:00AM ET on Tuesday Apr 30, 2024 by CNW Group

Apr 29, 2024

Qiagen Q1 Adjusted Earnings, Sales Decline; Q2 Outlook Issued, 2024 Guidance Affirms -- Shares Fall After Hours, from 4:48PM ET on Monday Apr 29, 2024 by MT Newswires

BioMarin Pharmaceutical Investors Overfocused on Roctavian, Distracted From Enzyme Replacement Therapies, UBS Says, from 2:26PM ET on Monday Apr 29, 2024 by MT Newswires

Apr 25, 2024

Scotiabank Adjusts Price Target on BioMarin Pharmaceutical to $83 From $85, Maintains Sector Perform Rating, from 11:43AM ET on Thursday Apr 25, 2024 by MT Newswires